Sign In
Buy CRIS
$0.500
-0.0025 (-0.498%)
At Close: Jun 03, 2026
Curis: Asymmetric Risk And Reward
04:02am, Sunday, 17'th Jul 2022
Curis share price has had dramatic fall since the FDA announced a hold on their “TakeAim” Leukemia study for Emavusertib on April 4, 2022, following the death of a patient. Recent price action sin
Curis Shares Gain On Encouraging Data Presentation From Blood Cancer Trials At ASCO Meeting
08:01am, Monday, 06'th Jun 2022
Curis Inc (NASDAQ: CRIS) presented clinical data from the TakeAim Lymphoma and TakeAim Leukemia studies at the 2022 American Society of Clinical Oncology Annual Meeting. The TakeAim Lymphoma Phase
Curis (CRIS) Q1 2022 Earnings Call Transcript
05:01am, Friday, 06'th May 2022 The Motley Fool
CRIS earnings call for the period ending March 31, 2022.
Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates
10:05pm, Thursday, 05'th May 2022 Zacks Investment Research
Curis (CRIS) delivered earnings and revenue surprises of -5.88% and 6.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates
07:34pm, Thursday, 05'th May 2022
Curis (CRIS) delivered earnings and revenue surprises of -5.88% and 6.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Curis Inc.'s (CRIS) CEO Jim Dentzer on Q1 2022 Results - Earnings Call Transcript
06:55pm, Thursday, 05'th May 2022
Curis, Inc. (NASDAQ:CRIS ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Craig West - Vice President of Investor Relations and Corporate Communications Jim Dentzer - Pre
Down 31.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Curis (CRIS)
01:35pm, Wednesday, 04'th May 2022 Zacks Investment Research
Curis (CRIS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ear
Down 31.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Curis (CRIS)
11:19am, Wednesday, 04'th May 2022
Curis (CRIS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ear
Voyager Therapeutics (VYGR) Moves 5.8% Higher: Will This Strength Last?
11:28am, Thursday, 21'st Apr 2022 Zacks Investment Research
Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the n
Curis (CRIS) Down on FDA Partial Clinical Hold on Lymphoma Study
03:57pm, Tuesday, 12'th Apr 2022 Zacks Investment Research
The FDA places a partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies. Shares fall.
After Leukemia Trial, FDA Puts Partial Hold On Curis' Lymphoma Study
02:50pm, Monday, 11'th Apr 2022
The FDA has placed a partial clinical hold on Curis Inc's (NASDAQ: CRIS) TakeAim Lymphoma study. The TakeAim Lymphoma study is a Phase 1/2 open-label dose-escalating clinical trial investigating em
Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2022
02:02pm, Tuesday, 05'th Apr 2022 Benzinga
Upgrades
Wolfe Research upgraded the previous rating for Landstar System Inc (NASDAQ:LSTR) from Underperform to Peer Perform. In the fourth quarter, Landstar System showed an EPS of $2.99, compared to
Curis to Present at 21st Annual Needham Virtual Healthcare Conference
08:00am, Tuesday, 05'th Apr 2022
LEXINGTON, Mass. , April 5, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced
Curis Plummets To 52-Week Low After FDA Clinical Hold On Blood Cancer Trial
09:10am, Monday, 04'th Apr 2022
The FDA has placed a partial clinical hold on Curis Inc's (NASDAQ: CRIS) TakeAim Leukemia Phase 1/2a study in relapsed or refractory (R/R) acute myeloid leukemia (AML) or high-risk myelodysplastic
Curis (CRIS) Q4 2021 Earnings Call Transcript
12:30pm, Friday, 25'th Feb 2022 The Motley Fool
CRIS earnings call for the period ending December 31, 2021.
